Cancer cachexia: Metabolic alterations and clinical manifestations

Nutrition

Volumn 13, Issue 1, 1997, Pages 1-7

  Tisdale, Michael J ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ANOREXIA; CACHEXIA; CANCER; CARBOHYDRATE METABOLISM; DISEASE ASSOCIATION; ENERGY EXPENDITURE; HUMAN; LIPID METABOLISM; METABOLIC DISORDER; MUSCLE ATROPHY; MUSCLE METABOLISM; NUTRITION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; TISSUE DEGENERATION;

EID: 0031020503     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0899-9007(96)00313-9     Document Type: Article

References (76)

1. De Wys WD. Management of cancer cachexia. Semin Oncol 1985;12:452
2. Inagaki J, Rodriguez V, Bodey GP. Causes of death in cancer patients. Cancer 1974;33:568
3. Warren S. The immediate causes of death in cancer. Am J Med Sci 1932;184:610
4. Kritchevsky SB, Wilcosky TC, Morris DL, et al. Changes in plasma lipid and lipoprotein cholesterol and weight prior to diagnosis of cancer. Cancer Res 1991;51:3198
5. Cohn SH, Gartenhaus W, Sawitsky A, et al. Compartmental body composition of cancer patients with measurement of total body nitrogen, potassium and water. Metabolism 1981;30:222
6. Heymsfield SB, McManus CB. Tissue components of weight loss in cancer patients. Cancer 1985;55:2238
7. Morrison SD. Control of food intake in cancer cachexia: a challenge and a tool. Physiol Behav 1976;17:705
8. Hollander DM, Ebert EC, Roberts AI, et al. Effects of tumor type and burden on carcass lipid depletion in mice. Surgery 1986;100:292
9. Costa G, Bewley P, Aragon M, et al. Anorexia and weight loss in cancer patients. Cancer Treat Rep 1981;65(suppl. 5):3
10. Costa G. Cachexia, the metabolic component of neoplastic diseases. Prog Exp Tumor Res 1963;3:321
11. Costa G, Lane WW, Vincent RG, et al. Weight loss and cachexia in lung cancer. Nutr Cancer 1980;2:98
12. Grosvenor M, Bulcavage L, Chlebowski RT. Symptoms potentially influencing weight loss in a cancer population. Cancer 1989;63:330
13. Evans WK, Makuch R, Clamon GH, et al. Limited impact of total parenteral nutrition on nutritional status during treatment for small cell lung cancer. Cancer Res 1985;45:3347
14. Loprinzi CL, Michalak JC, Schaid DJ, et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol 1993;11:762
15. Loprinzi CL, Schaid DJ, Dose AM, et al. Body composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol 1993;11:152
16. Knox LS, Crosby LO, Feurer ID, et al. Energy expenditure in malnourished cancer patients. Ann Surg 1983;197:152
17. Nixon DW, Kutner M, Heymsfield S, et al. Resting energy expenditure in lung and colon cancer. Metabolism 1988;37:1059
18. Lundmark L, Bennyard K, Eden E, et al. Resting energy expenditure in malnourished patients with and without cancer. Gastroenterology 1984;87:407
19. Fredix EWHM, Soeters PB, Wouters EFM, et al. Energy balance in relation to cancer cachexia. Clin Nutr 1990;9:319
20. Falconer JS, Fearon KCH, Plester CE, et al. Cytokines, the acute-phase response and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg 1994;219:325
21. Hyltander A, Drott C, Körner U, et al. Elevated energy expenditure in cancer patients with solid tumours. Eur J Cancer 1991;27:9
22. Holroyde CP, Gabuzda TG, Putnam RC, et al. Altered glucose metabolism in metastatic carcinoma. Cancer Res 1975;35:3710
23. Lundholm K, Holm G, Schersten T. Gluconeogenesis from alanine in patients with progressive malignant disease. Cancer Res 1979;33:1968
24. Tayek JA. A review of cancer cachexia and abnormal glucose metabolism in humans with cancer. J Am Coll Nutr 1992;11:445
25. Rofe AM, Bourgeosis CS, Coyle P, et al. Altered insulin response to glucose in weight-losing cancer patients. Anticancer Res 1994;4:647
26. Burt ME, Brennan MF. Nutritional support of the patient with esophageal cancer. Semin Oncol 1984;11:127
27. Kralovic RC, Zepp EA, Cenedella RJ. Studies on the mechanism of carcass fat depletion in experimental cancer. Eur J Cancer 1977;13:1071
28. Shaw JH, Wolfe RR. Fatty acid and glycerol kinetics in septic patients and in patients with gastrointestinal cancer. Ann Surg 1987;205:368
29. Mueller PS, Watkin DM. Plasma unesterified fatty acid concentrations in neoplastic disease. J Lab Clin Med 1961;57:95
30. Hays ET. Serum lipids in human cancer. J Surg Res 1969;57:95
31. Waterhouse C, Nye WHR. Metabolic effects of infused triglycerides. Metabolism 1961;10:403
32. Hussey HJ, Tisdale MJ. Effect of polyunsaturated fatty acids on the growth of murine colon adenocarcinomas in vitro and in vivo. Br J Cancer 1994;70:6
33. Tisdale MJ, Beck SA. Inhibition of tumour-induced lipolysis in vitro and cachexia and tumour growth in vivo by eicosapentaenoic acid. Biochem Pharmacol 1991;41:103
34. Clark CM, Goodlad GAJ. Depletion of proteins of phasic and tonic muscles in tumor-bearing rats. Eur J Cancer 1971;7:3
35. Gray GE, Meguid MM. Can total parenteral nutrition reverse hypoalbuminemia in oncology patients? Nutrition 1990;6:225
36. Lundholm K, Bylund AC, Holm J, et al. Skeletal muscle metabolism in patients with malignant tumour. Eur J Cancer 1976;12:465
37. Fearon KCH, McMillan DC, Preston T, et al. Elevated circulating interleukin-6 is associated with an acute phase response, but reduced fixed hepatic protein synthesis in patients with cancer. Ann Surg 1991;213:26
38. O'Keefe SJD, Ogden J, Ramjee G, et al. Contribution of elevated protein turnover and anorexia to cachexia in patients with hepatocellular carcinoma. Cancer Res 1990;50:1226
39. Llovera M, Garcia-Martinez C, Agell N, et al. Ubiquitin gene expression is increased in skeletal muscle of tumour-bearing rats. FEBS Lett 1994;338:311
40. Smith KL, Tisdale MJ. Mechanism of muscle protein degradation in cancer cachexia. Br J Cancer 1993;68:314
41. Belizario JE, Katz M, Raw CI. Bioactivity of skeletal muscle proteolysis-inducing factors in the plasma proteins from cancer patients with weight loss. Br J Cancer 1991;63:705
42. Beutler B, Greenwald D, Hulmes JD, et al. Identity of tumour necrosis factor and the macrophage secreted factor cachectin. Nature 1985;316:552
43. Starnes HFJ, Warren RS, Jeevanandum M, et al. Tumor necrosis factor and the acute metabolic response to tissue injury in man. J Clin Invest 1988;82:1321
44. Bartsch HH, Pfizenmaier K, Schroeder M, et al. Intralesional application of recombinant human tumor necrosis factor alpha induces local tumor regressions in patients with advanced malignancies. Eur J Cancer Clin Oncol 1989;25:287
45. Grunfeld C, Wilking H, Neese R, et al. Persistence of the hypertriglyceridemic effect of tumor necrosis factor despite development of tachyphylaxis to its anorectic/cachectic effects in rats. Cancer Res 1989;49:2554
46. Grunfeld C, Kotler DP, Hamadeh R, et al. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989;86:27
47. Oliff A, Defo-Jones D, Boyer M, et al. Tumors secreting human TNF/cachectin induce cachexia in mice. Cell 1987;50:555
48. Buck M, Chojkier M. Muscle wasting and dedifferentiation induced by oxidative stress in a murine model of cachexia is prevented by inhibitors of nitric oxide synthesis and antioxidants. EMBO J 1996;15:1753
49. Lonnroth C, Moldawer LL, Gelin J, et al. Tumor necrosis factor-α and interleukin-Iα production in cachectic, tumor-bearing mice. Int J Cancer 1990;46:889
50. Socher SH, Martinez D, Craig JB, et al. Tumor necrosis factor not detectable in patients with clinical cancer cachexia. J Natl Cancer Inst 1988;80:595
51. Selby P, Hobbs S, Viner C, et al. Tumor necrosis factor in man. Clinical and biological observations. Br J Cancer 1987;56:803
52. Balkwill F, Burke F, Talbot D, et al. Evidence for tumour necrosis factor/cachectin production in cancer. Lancet 1987;ii:1229
53. Saarinen UM, Koskels E-K, Teppo AM, et al. Tumor necrosis factor in children with malignancies. Cancer Res 1990;50:592
54. Gelin J, Moldawer LL, Lonroth C, et al. Role of endogenous tumor necrosis factor a and interleukin I for experimental tumor growth and development of cancer cachexia. Cancer Res 1991;51:415
55. Lahdevirta J, Maury CPJ, Teppo AM, et al. Elevated levels of circulating cachectin/tumor necrosis factor in patients with the acquired immunodeficiency syndrome. Am J Med 1988;85:289
56. Thompson MP, Cooper ST, Parry BR, et al. Increased expression of the mRNA for the hormone-sensitive lipase in adipose tissue of cancer patients. Biochim Biophys Acta 1993;1180:236
57. Sherry BA, Gelin G, Fong Y, et al. Anticachectin/tumor necrosis factor-α antibodies attenuate development of cachexia in tumor models. FASEBJ 1989;3:1956
58. Mulligan HD, Mahony SM, Ross JA, et al. Weight loss in a murine cachexia model is not associated with the cytokines tumor necrosis factor alpha or interleukin-6. Cancer Lett 1992;65:239
59. Strassmann G, Fong M, Kenney JS, et al. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 1992;89:1681
60. Yoneda T, Alsira MA, Chavez JB, et al. Evidence that tumor necrosis factor plays a pathogenetic role in the paraneoplastic syndrome of cachexia, hypercalcemia and leukocytosis in a human tumor in nude mice. J Clin Invest 1991;87:977
61. Goldberg RM, Loprinzi CL, Malliard JA. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double blind, placebo-controlled trial. J Clin Oncol 1995;13:2856
62. Soda K, Kawakami M, Kashii K, et al. Manifestation of cancer cachexia induced by colon 26 adenocarcinoma are not fully ascribable to interleukin-6. Int J Cancer 1995;62:332
63. Black K, Garrett IR, Mundy GR. Chinese hamster ovary cells transfected with the murine IL-6 gene cause hypercalcemia as well as cachexia, leukocytosis and thrombosis in tumor-bearing nude mice. Endocrinology 1991;128:2657
64. Garcia-Martinez C, Lopez-Soriano FJ, Argiles JM. Interleukin-6 does not activate protein breakdown in rat skeletal muscle. Cancer Lett 1994;76:1
65. Yamagewa H, Sone S, Takahashi Y, et al. Serum levels of interleukin 6 in patients with lung cancer. Br J Cancer 1995;71:1095
66. Strassmann G, Masui Y, Chizzonite R, et al. Mechanisms of experimental cancer cachexia. Local involvement of IL-1 in colon-26 tumor. J Immunol 1993;150:2341
67. 2 production in rat skeletal muscle in fever signaled by a macrophage product distinct from interleukin-1 or other known monokines. J Clin Invest 1988;81:1378
68. Mori M, Yamaguchi J, Honda S, et al. Cancer cachexia syndrome developed in nude mice bearing melanoma cells producing leukemia inhibitory factor. Cancer Res 1991;51:6656
69. Marshall MK, Doerrler W, Feingold KR, et al. Leukemia inhibitory factor induces changes in lipid metabolism in cultured adipocytes. Endocrinology 1994;135:141
70. Matthys P, Heremans H, Opdenakker G, et al. Anti-interferon-γ antibody treatment, growth of Lewis lung tumours in mice and tumour-associated cachexia. Eur J Cancer 1991;27:182
71. Masuno H, Yoshimura H, Ogawa N, et al. Isolation of a lipolytic factor (toxohormone-L) from ascites fluid of patients with hepatoma and its effect on feeding behaviour. Eur J Cancer Clin Oncol 1984;20:1177
72. Taylor DD, Gercel-Taylor C, Jenis LG, et al. Identification of a human tumor-derived lipolysis promoting factor. Cancer Res 1992;82:829
73. Beck SA, Mulligan HD, Tisdale MJ. Lipolytic factors associated with murine and human cancer cachexia. J Natl Cancer Inst 1990;82:1922
74. Beck SA, Groundwater P, Barton C, et al. Alterations in serum lipolytic activity of cancer patients with response to therapy. Br J Cancer 1990;62:822
75. Wigmore SJ, Ross JA, Falconer JS, et al. The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition 1996;12(suppl.):S27
76. Todorov P, Cariuk P, McDevitt T, et al. Characterization of a cancer cachectic factor. Nature 1996;379:739